Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | HTT | P42858 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.97 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | METAP2 | P50579 | 5/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.97 |
| ▸ | MMP14 | P50281 | 3/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.97 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.97 |
| ▸ | USP2 | O75604 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | HPGD | P15428 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clioquinol SCHEMBL11749381 | 0.98 | KDM4E (1.00) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL30592904 | 0.98 | KDM4E (1.00) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL29370380 | 0.98 | KDM4E (1.00) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL3967 | 0.98 | KDM4E (1.00) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL28198183 | 0.97 | KDM4E (0.97) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL27671588 | 0.97 | KDM4E (0.97) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL28524321 | 0.97 | KDM4E (0.97) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL28531298 | 0.97 | KDM4E (0.97) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL28529781 | 0.97 | KDM4E (0.97) | KDM4ELMNAMEN1HTTKMT2A | |
| Clioquinol SCHEMBL9339556 | 0.97 | KDM4E (0.97) | KDM4ELMNAMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230087131-A1 | LIQUID DRESSING COMPOSITIONS AND THEIR VETERINARY USES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-03-23 | — | — | US | disclosed |
| EP-4009988-A1 | LIQUID DRESSING COMPOSITIONS AND THEIR VETERINARY USES | Cambridge Enterprise Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| EP-4009987-A1 | LIQUID DRESSING COMPOSITIONS AND THEIR USES | Cambridge Enterprise Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| CN-114514042-A | Liquid dressing composition and veterinary use thereof | 剑桥有限公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2021023886-A1 | LIQUID DRESSING COMPOSITIONS AND THEIR VETERINARY USES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021023885-A1 | LIQUID DRESSING COMPOSITIONS AND THEIR USES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2021-02-11 | — | — | WO | disclosed |
| US-20180369143-A1 | METAL COMPLEXED THERAPEUTIC AGENTS AND LIPID-BASED NANOPARTICULATE FORMULATIONS THEREOF | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2018-12-27 | — | — | US | disclosed |
| CN-108883117-A | Metal complexed therapeutic agents and lipid based nanoparticle formulations thereof | 英属哥伦比亚癌症研究分支机构 | 2018-11-23 | — | — | CN | disclosed |
| EP-3389665-A1 | METAL COMPLEXED THERAPEUTIC AGENTS AND LIPID-BASED NANOPARTICULATE FORMULATIONS THEREOF | British Columbia Cancer Agency Branch (CA) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017100925-A1 | METAL COMPLEXED THERAPEUTIC AGENTS AND LIPID-BASED NANOPARTICULATE FORMULATIONS THEREOF | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369143-A1 | METAL COMPLEXED THERAPEUTIC AGENTS AND LIPID-BASED NANOPARTICULATE FORMULATIONS THEREOF | LIPA, SLC40A1, SLC30A6 | KDM4E 4138/4885LMNA 1631/4885MEN1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.